메뉴 건너뛰기




Volumn 53, Issue 12, 2014, Pages 1137-1147

Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome

Author keywords

[No Author keywords available]

Indexed keywords

ELOSULFASE ALFA; NEUTRALIZING ANTIBODY; PLACEBO; GALNS PROTEIN, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

EID: 84922002913     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0173-y     Document Type: Article
Times cited : (35)

References (16)
  • 2
    • 0031447880 scopus 로고    scopus 로고
    • Incidence of the mucopolysaccharidoses in Northern Ireland
    • COI: 1:STN:280:DyaK1c7gt1ynsg%3D%3D, PID: 9439667
    • Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101:355–8.
    • (1997) Hum Genet , vol.101 , pp. 355-358
    • Nelson, J.1
  • 3
    • 0344033744 scopus 로고    scopus 로고
    • Incidence of the mucopolysaccharidoses in Western Australia
    • PID: 14608657
    • Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A:310–3.
    • (2003) Am J Med Genet A , vol.123A , pp. 310-313
    • Nelson, J.1    Crowhurst, J.2    Carey, B.3    Greed, L.4
  • 6
    • 77957870094 scopus 로고    scopus 로고
    • Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice
    • PID: 20808938
    • Dvorak-Ewell M, Wendt D, Hague C, Christianson T, Koppaka V, Crippen D, Kakkis E, Vellard M. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 2010;5:e12194.
    • (2010) PLoS One , vol.5 , pp. e12194
    • Dvorak-Ewell, M.1    Wendt, D.2    Hague, C.3    Christianson, T.4    Koppaka, V.5    Crippen, D.6    Kakkis, E.7    Vellard, M.8
  • 7
    • 84872463080 scopus 로고    scopus 로고
    • Long term outcomes of a phase 1/2, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and efficacy of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome)
    • Hendriksz C, Vellodi A, Jones S, Takkele H, Lee S, Chesler S, Decker C. Long term outcomes of a phase 1/2, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and efficacy of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). Mol Genet Metab. 2012;105:S35.
    • (2012) Mol Genet Metab , vol.105 , pp. S35
    • Hendriksz, C.1    Vellodi, A.2    Jones, S.3    Takkele, H.4    Lee, S.5    Chesler, S.6    Decker, C.7
  • 10
    • 33947615114 scopus 로고    scopus 로고
    • International Morquio A registry: clinical manifestation and natural course of Morquio A disease
    • PID: 17347914
    • Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165–74.
    • (2007) J Inherit Metab Dis , vol.30 , pp. 165-174
    • Montaño, A.M.1    Tomatsu, S.2    Gottesman, G.S.3    Smith, M.4    Orii, T.5
  • 11
    • 84922006258 scopus 로고    scopus 로고
    • Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IV A (Morquio A syndrome). Briefing document for the endocrinologic and metabolic drugs advisory committee, FDA,. 19 Nov 2013, p. 53
    • BioMarin Pharmaceutical. Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IV A (Morquio A syndrome). Briefing document for the endocrinologic and metabolic drugs advisory committee, FDA, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM375127.pdf. 19 Nov 2013, p. 53.
    • BioMarin Pharmaceutical
  • 12
    • 85018144881 scopus 로고    scopus 로고
    • Naglazyme (galsulfase): highlights of prescribing information
    • BioMarin Pharmaceutical. Naglazyme (galsulfase): highlights of prescribing information, Novato; 2013.
    • (2013) Novato
  • 13
    • 84922006256 scopus 로고    scopus 로고
    • Highlights of prescribing information, Novato and Cambridge:
    • BioMarin Pharmaceutical, Genzyme Corporation, Aldurazyme (laronidase): Highlights of prescribing information, Novato and Cambridge; 2013.
    • (2013) Aldurazyme (laronidase)
  • 14
    • 27744493202 scopus 로고    scopus 로고
    • Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase
    • PID: 15930196
    • Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, Yu ZF, Swiedler SJ, Hopwood JJ, MPS VI Study Group. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681–9.
    • (2005) Pediatrics , vol.115 , pp. e681-e689
    • Harmatz, P.1    Ketteridge, D.2    Giugliani, R.3    Guffon, N.4    Teles, E.L.5    Miranda, M.C.6    Yu, Z.F.7    Swiedler, S.J.8    Hopwood, J.J.9    MPS VI Study Group10
  • 15
    • 0028449393 scopus 로고
    • Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells
    • COI: 1:CAS:528:DyaK2cXlslOku7w%3D, PID: 7950365
    • Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells. Protein Expr Purif. 1994;5:225–32.
    • (1994) Protein Expr Purif. , vol.5 , pp. 225-232
    • Kakkis, E.D.1    Matynia, A.2    Jonas, A.J.3    Neufeld, E.F.4
  • 16
    • 84922002638 scopus 로고    scopus 로고
    • Highlights of prescribing information, Lexington:
    • Shire Human Genetic Therapies, Elaprase (idursulfase): Highlights of prescribing information, Lexington; 2013.
    • (2013) Elaprase (idursulfase)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.